A comparative ethical analysis of the Egyptian clinical research law
In this study, we examined the ethical implications of Egypt's new clinical trial law, employing the ethical framework proposed by Emanuel et al. and comparing it to various national and supranational laws. This analysis is crucial as Egypt, considered a high-growth pharmaceutical market, has b...
Saved in:
| Published in | BMC medical ethics Vol. 25; no. 1; pp. 48 - 14 |
|---|---|
| Main Authors | , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
BioMed Central Ltd
30.04.2024
BioMed Central BMC |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1472-6939 1472-6939 |
| DOI | 10.1186/s12910-024-01040-0 |
Cover
Loading…
| Abstract | In this study, we examined the ethical implications of Egypt's new clinical trial law, employing the ethical framework proposed by Emanuel et al. and comparing it to various national and supranational laws. This analysis is crucial as Egypt, considered a high-growth pharmaceutical market, has become an attractive location for clinical trials, offering insights into the ethical implementation of bioethical regulations in a large population country with a robust healthcare infrastructure and predominantly treatment-naïve patients.
We conducted a comparative analysis of Egyptian law with regulations from Sweden and France, including the EU Clinical Trials Regulation, considering ethical human subject research criteria, and used a directed approach to qualitative content analysis to examine the laws and regulations. This study involved extensive peer scrutiny, frequent debriefing sessions, and collaboration with legal experts with relevant international legal expertise to ensure rigorous analysis and interpretation of the laws.
On the rating of the seven different principles (social and scientific values, scientific validity, fair selection of participants, risk-benefit ratio, independent review, informed consent and respect for participants) Egypt, France, and EU regulations had comparable scores. Specific principles (Social Value, Scientific Value, and Fair selection of participants) were challenging to directly identify due to certain regulations embodying 'implicit' principles more than explicitly stated ones.
The analysis underscores Egypt's alignment with internationally recognized ethical principles, as outlined by Emanuel et al., through its comparison with French, Swedish, and EU regulations, emphasizing the critical need for Egypt to continuously refine its ethical regulations to safeguard participant protection and research integrity. Key issues identified include the necessity to clarify and standardize the concept of social value in research, alongside concerns regarding the expertise and impartiality of ethical review boards, pointing towards a broader agenda for enhancing research ethics in Egypt and beyond. |
|---|---|
| AbstractList | In this study, we examined the ethical implications of Egypt's new clinical trial law, employing the ethical framework proposed by Emanuel et al. and comparing it to various national and supranational laws. This analysis is crucial as Egypt, considered a high-growth pharmaceutical market, has become an attractive location for clinical trials, offering insights into the ethical implementation of bioethical regulations in a large population country with a robust healthcare infrastructure and predominantly treatment-naïve patients. We conducted a comparative analysis of Egyptian law with regulations from Sweden and France, including the EU Clinical Trials Regulation, considering ethical human subject research criteria, and used a directed approach to qualitative content analysis to examine the laws and regulations. This study involved extensive peer scrutiny, frequent debriefing sessions, and collaboration with legal experts with relevant international legal expertise to ensure rigorous analysis and interpretation of the laws. On the rating of the seven different principles (social and scientific values, scientific validity, fair selection of participants, risk-benefit ratio, independent review, informed consent and respect for participants) Egypt, France, and EU regulations had comparable scores. Specific principles (Social Value, Scientific Value, and Fair selection of participants) were challenging to directly identify due to certain regulations embodying 'implicit' principles more than explicitly stated ones. The analysis underscores Egypt's alignment with internationally recognized ethical principles, as outlined by Emanuel et al., through its comparison with French, Swedish, and EU regulations, emphasizing the critical need for Egypt to continuously refine its ethical regulations to safeguard participant protection and research integrity. Key issues identified include the necessity to clarify and standardize the concept of social value in research, alongside concerns regarding the expertise and impartiality of ethical review boards, pointing towards a broader agenda for enhancing research ethics in Egypt and beyond. Background In this study, we examined the ethical implications of Egypt's new clinical trial law, employing the ethical framework proposed by Emanuel et al. and comparing it to various national and supranational laws. This analysis is crucial as Egypt, considered a high-growth pharmaceutical market, has become an attractive location for clinical trials, offering insights into the ethical implementation of bioethical regulations in a large population country with a robust healthcare infrastructure and predominantly treatment-naïve patients. Methods We conducted a comparative analysis of Egyptian law with regulations from Sweden and France, including the EU Clinical Trials Regulation, considering ethical human subject research criteria, and used a directed approach to qualitative content analysis to examine the laws and regulations. This study involved extensive peer scrutiny, frequent debriefing sessions, and collaboration with legal experts with relevant international legal expertise to ensure rigorous analysis and interpretation of the laws. Results On the rating of the seven different principles (social and scientific values, scientific validity, fair selection of participants, risk-benefit ratio, independent review, informed consent and respect for participants) Egypt, France, and EU regulations had comparable scores. Specific principles (Social Value, Scientific Value, and Fair selection of participants) were challenging to directly identify due to certain regulations embodying 'implicit' principles more than explicitly stated ones. Conclusion The analysis underscores Egypt's alignment with internationally recognized ethical principles, as outlined by Emanuel et al., through its comparison with French, Swedish, and EU regulations, emphasizing the critical need for Egypt to continuously refine its ethical regulations to safeguard participant protection and research integrity. Key issues identified include the necessity to clarify and standardize the concept of social value in research, alongside concerns regarding the expertise and impartiality of ethical review boards, pointing towards a broader agenda for enhancing research ethics in Egypt and beyond. Keywords: Biomedical laws, Ethical principles, Egypt, Clinical trials, Social value In this study, we examined the ethical implications of Egypt's new clinical trial law, employing the ethical framework proposed by Emanuel et al. and comparing it to various national and supranational laws. This analysis is crucial as Egypt, considered a high-growth pharmaceutical market, has become an attractive location for clinical trials, offering insights into the ethical implementation of bioethical regulations in a large population country with a robust healthcare infrastructure and predominantly treatment-naïve patients.BACKGROUNDIn this study, we examined the ethical implications of Egypt's new clinical trial law, employing the ethical framework proposed by Emanuel et al. and comparing it to various national and supranational laws. This analysis is crucial as Egypt, considered a high-growth pharmaceutical market, has become an attractive location for clinical trials, offering insights into the ethical implementation of bioethical regulations in a large population country with a robust healthcare infrastructure and predominantly treatment-naïve patients.We conducted a comparative analysis of Egyptian law with regulations from Sweden and France, including the EU Clinical Trials Regulation, considering ethical human subject research criteria, and used a directed approach to qualitative content analysis to examine the laws and regulations. This study involved extensive peer scrutiny, frequent debriefing sessions, and collaboration with legal experts with relevant international legal expertise to ensure rigorous analysis and interpretation of the laws.METHODSWe conducted a comparative analysis of Egyptian law with regulations from Sweden and France, including the EU Clinical Trials Regulation, considering ethical human subject research criteria, and used a directed approach to qualitative content analysis to examine the laws and regulations. This study involved extensive peer scrutiny, frequent debriefing sessions, and collaboration with legal experts with relevant international legal expertise to ensure rigorous analysis and interpretation of the laws.On the rating of the seven different principles (social and scientific values, scientific validity, fair selection of participants, risk-benefit ratio, independent review, informed consent and respect for participants) Egypt, France, and EU regulations had comparable scores. Specific principles (Social Value, Scientific Value, and Fair selection of participants) were challenging to directly identify due to certain regulations embodying 'implicit' principles more than explicitly stated ones.RESULTSOn the rating of the seven different principles (social and scientific values, scientific validity, fair selection of participants, risk-benefit ratio, independent review, informed consent and respect for participants) Egypt, France, and EU regulations had comparable scores. Specific principles (Social Value, Scientific Value, and Fair selection of participants) were challenging to directly identify due to certain regulations embodying 'implicit' principles more than explicitly stated ones.The analysis underscores Egypt's alignment with internationally recognized ethical principles, as outlined by Emanuel et al., through its comparison with French, Swedish, and EU regulations, emphasizing the critical need for Egypt to continuously refine its ethical regulations to safeguard participant protection and research integrity. Key issues identified include the necessity to clarify and standardize the concept of social value in research, alongside concerns regarding the expertise and impartiality of ethical review boards, pointing towards a broader agenda for enhancing research ethics in Egypt and beyond.CONCLUSIONThe analysis underscores Egypt's alignment with internationally recognized ethical principles, as outlined by Emanuel et al., through its comparison with French, Swedish, and EU regulations, emphasizing the critical need for Egypt to continuously refine its ethical regulations to safeguard participant protection and research integrity. Key issues identified include the necessity to clarify and standardize the concept of social value in research, alongside concerns regarding the expertise and impartiality of ethical review boards, pointing towards a broader agenda for enhancing research ethics in Egypt and beyond. Background In this study, we examined the ethical implications of Egypt’s new clinical trial law, employing the ethical framework proposed by Emanuel et al. and comparing it to various national and supranational laws. This analysis is crucial as Egypt, considered a high-growth pharmaceutical market, has become an attractive location for clinical trials, offering insights into the ethical implementation of bioethical regulations in a large population country with a robust healthcare infrastructure and predominantly treatment-naïve patients. Methods We conducted a comparative analysis of Egyptian law with regulations from Sweden and France, including the EU Clinical Trials Regulation, considering ethical human subject research criteria, and used a directed approach to qualitative content analysis to examine the laws and regulations. This study involved extensive peer scrutiny, frequent debriefing sessions, and collaboration with legal experts with relevant international legal expertise to ensure rigorous analysis and interpretation of the laws. Results On the rating of the seven different principles (social and scientific values, scientific validity, fair selection of participants, risk-benefit ratio, independent review, informed consent and respect for participants) Egypt, France, and EU regulations had comparable scores. Specific principles (Social Value, Scientific Value, and Fair selection of participants) were challenging to directly identify due to certain regulations embodying 'implicit' principles more than explicitly stated ones. Conclusion The analysis underscores Egypt's alignment with internationally recognized ethical principles, as outlined by Emanuel et al., through its comparison with French, Swedish, and EU regulations, emphasizing the critical need for Egypt to continuously refine its ethical regulations to safeguard participant protection and research integrity. Key issues identified include the necessity to clarify and standardize the concept of social value in research, alongside concerns regarding the expertise and impartiality of ethical review boards, pointing towards a broader agenda for enhancing research ethics in Egypt and beyond. Abstract Background In this study, we examined the ethical implications of Egypt’s new clinical trial law, employing the ethical framework proposed by Emanuel et al. and comparing it to various national and supranational laws. This analysis is crucial as Egypt, considered a high-growth pharmaceutical market, has become an attractive location for clinical trials, offering insights into the ethical implementation of bioethical regulations in a large population country with a robust healthcare infrastructure and predominantly treatment-naïve patients. Methods We conducted a comparative analysis of Egyptian law with regulations from Sweden and France, including the EU Clinical Trials Regulation, considering ethical human subject research criteria, and used a directed approach to qualitative content analysis to examine the laws and regulations. This study involved extensive peer scrutiny, frequent debriefing sessions, and collaboration with legal experts with relevant international legal expertise to ensure rigorous analysis and interpretation of the laws. Results On the rating of the seven different principles (social and scientific values, scientific validity, fair selection of participants, risk-benefit ratio, independent review, informed consent and respect for participants) Egypt, France, and EU regulations had comparable scores. Specific principles (Social Value, Scientific Value, and Fair selection of participants) were challenging to directly identify due to certain regulations embodying 'implicit' principles more than explicitly stated ones. Conclusion The analysis underscores Egypt's alignment with internationally recognized ethical principles, as outlined by Emanuel et al., through its comparison with French, Swedish, and EU regulations, emphasizing the critical need for Egypt to continuously refine its ethical regulations to safeguard participant protection and research integrity. Key issues identified include the necessity to clarify and standardize the concept of social value in research, alongside concerns regarding the expertise and impartiality of ethical review boards, pointing towards a broader agenda for enhancing research ethics in Egypt and beyond. BackgroundIn this study, we examined the ethical implications of Egypt’s new clinical trial law, employing the ethical framework proposed by Emanuel et al. and comparing it to various national and supranational laws. This analysis is crucial as Egypt, considered a high-growth pharmaceutical market, has become an attractive location for clinical trials, offering insights into the ethical implementation of bioethical regulations in a large population country with a robust healthcare infrastructure and predominantly treatment-naïve patients.MethodsWe conducted a comparative analysis of Egyptian law with regulations from Sweden and France, including the EU Clinical Trials Regulation, considering ethical human subject research criteria, and used a directed approach to qualitative content analysis to examine the laws and regulations. This study involved extensive peer scrutiny, frequent debriefing sessions, and collaboration with legal experts with relevant international legal expertise to ensure rigorous analysis and interpretation of the laws.ResultsOn the rating of the seven different principles (social and scientific values, scientific validity, fair selection of participants, risk-benefit ratio, independent review, informed consent and respect for participants) Egypt, France, and EU regulations had comparable scores. Specific principles (Social Value, Scientific Value, and Fair selection of participants) were challenging to directly identify due to certain regulations embodying 'implicit' principles more than explicitly stated ones.ConclusionThe analysis underscores Egypt's alignment with internationally recognized ethical principles, as outlined by Emanuel et al., through its comparison with French, Swedish, and EU regulations, emphasizing the critical need for Egypt to continuously refine its ethical regulations to safeguard participant protection and research integrity. Key issues identified include the necessity to clarify and standardize the concept of social value in research, alongside concerns regarding the expertise and impartiality of ethical review boards, pointing towards a broader agenda for enhancing research ethics in Egypt and beyond. In this study, we examined the ethical implications of Egypt's new clinical trial law, employing the ethical framework proposed by Emanuel et al. and comparing it to various national and supranational laws. This analysis is crucial as Egypt, considered a high-growth pharmaceutical market, has become an attractive location for clinical trials, offering insights into the ethical implementation of bioethical regulations in a large population country with a robust healthcare infrastructure and predominantly treatment-naïve patients. We conducted a comparative analysis of Egyptian law with regulations from Sweden and France, including the EU Clinical Trials Regulation, considering ethical human subject research criteria, and used a directed approach to qualitative content analysis to examine the laws and regulations. This study involved extensive peer scrutiny, frequent debriefing sessions, and collaboration with legal experts with relevant international legal expertise to ensure rigorous analysis and interpretation of the laws. On the rating of the seven different principles (social and scientific values, scientific validity, fair selection of participants, risk-benefit ratio, independent review, informed consent and respect for participants) Egypt, France, and EU regulations had comparable scores. Specific principles (Social Value, Scientific Value, and Fair selection of participants) were challenging to directly identify due to certain regulations embodying 'implicit' principles more than explicitly stated ones. The analysis underscores Egypt's alignment with internationally recognized ethical principles, as outlined by Emanuel et al., through its comparison with French, Swedish, and EU regulations, emphasizing the critical need for Egypt to continuously refine its ethical regulations to safeguard participant protection and research integrity. Key issues identified include the necessity to clarify and standardize the concept of social value in research, alongside concerns regarding the expertise and impartiality of ethical review boards, pointing towards a broader agenda for enhancing research ethics in Egypt and beyond. |
| ArticleNumber | 48 |
| Audience | Academic |
| Author | Slokenberga, Santa Ancillotti, Mirko Matar, Amal Martin, Sylvia |
| Author_xml | – sequence: 1 givenname: Sylvia surname: Martin fullname: Martin, Sylvia – sequence: 2 givenname: Mirko surname: Ancillotti fullname: Ancillotti, Mirko – sequence: 3 givenname: Santa surname: Slokenberga fullname: Slokenberga, Santa – sequence: 4 givenname: Amal surname: Matar fullname: Matar, Amal |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38689214$$D View this record in MEDLINE/PubMed https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-527433$$DView record from Swedish Publication Index |
| BookMark | eNqNk0tv1DAQxyNURB_wBTigSFxAIsWv2PGpWvUBKyoV8ejVcib2rlfZeLGTlv329e6W0iAOlQ8ejX_zH8_Yc5jtdb4zWfYao2OMK_4xYiIxKhBhBcKIJetZdoCZIAWXVO49svezwxgXCGFRUfIi26cVryTB7CA7m-TglysddO9uTG76uQPd5rrT7Tq6mHub93OTn8_Wq97pLofWdVsimGh0gHne6tuX2XOr22he3e9H2c-L8x-nn4vLq0_T08llAbxkfcGbshEG6wbVDKghtuIWldJwTjmUNVQVByIs4JLb2toaJKosYrQRSDQgBT3KpjvdxuuFWgW31GGtvHZq6_BhpnToHbRGUUCopgC1QakLEmqJeIMJSdlKhDRNWh92WvHWrIZ6pHbmridbtWFQJRGMbvCTHZ7YpWnAdH3Q7ShqfNK5uZr5G4VxKpGzMim8u1cI_tdgYq-WLoJpW90ZP0RFEZMCc17xhL79B134IaQn2VAlw4JzWf2lZjoV7DrrU2LYiKqJkBRJRuTm4sf_odJqzNJB-lDWJf8o4P0oIDG9-d3P9BCj-vJ1-mR2-v3b09mr6zH75nG3H9r8598mgOwACD7GYOwDgpHaDIfaDYdKw6G2w6EQvQNG3_xT |
| Cites_doi | 10.1080/10508422.2015.1096207 10.1016/S1470-2045(06)70618-0 10.1177/1049732305276687 10.1086/381709 10.1001/jama.2013.281053 10.1186/s43066-019-0010-y 10.1177/15562646221093218 10.1126/science.322.5899.214 10.55202/ajlpp.v1i3.71 10.1177/2382120519883887 10.1097/DCC.0000000000000186 10.1093/oso/9780195168655.001.0001 10.1177/1747016116649993 10.1097/00005650-200003000-00010 10.1097/01.CCM.0000054907.33928.48 10.1080/15265161.2020.1851812 10.1016/S0140-6736(14)61315-5 10.1177/2158244014543782 10.1177/1556264614553172 10.1136/bmjopen-2019-031763 10.5435/JAAOS-D-19-00146 10.1525/jer.2013.8.5.40 10.1111/spc3.12506 10.17576/malim-2020-2101-06 10.1080/09650792.2018.1450771 10.1016/S2542-5196(20)30242-4 10.1001/jama.283.20.2701 10.1017/S0963180106060361 10.1177/17470161231179663 10.1007/s11673-020-10069-w 10.1016/j.cct.2021.106517 10.1186/1745-6215-15-335 10.1177/1403494819863514 10.1186/1472-6939-15-66 10.1016/j.jmau.2014.03.003 10.3389/fmed.2021.715796 10.1007/s10805-021-09430-4 10.1007/s11948-017-9945-8 10.1590/s1806-37562018000000164 10.1016/j.bpobgyn.2016.12.006 10.1186/s12909-022-03250-9 10.1080/15265161.2019.1701731 10.1111/dewb.12191 10.1016/j.cct.2014.02.005 10.1007/s10728-014-0284-5 10.1111/bioe.12786 |
| ContentType | Journal Article |
| Copyright | 2024. The Author(s). COPYRIGHT 2024 BioMed Central Ltd. 2024. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Author(s) 2024 |
| Copyright_xml | – notice: 2024. The Author(s). – notice: COPYRIGHT 2024 BioMed Central Ltd. – notice: 2024. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: The Author(s) 2024 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM IOV ISR KPI 3V. 7X7 7XB 88C 88E 8FI 8FJ 8FK AABKS ABSDQ ABUWG AFKRA AZQEC BENPR CCPQU COVID DWQXO FYUFA GHDGH K9. M0S M0T M1P PGAAH PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM ACNBI ADTPV AOWAS D8T DF2 ZZAVC DOA |
| DOI | 10.1186/s12910-024-01040-0 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Opposing Viewpoints In Context Gale In Context: Science Gale In Context: Global Issues ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Healthcare Administration Database (Alumni) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Philosophy Collection Philosophy Database ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College Coronavirus Research Database ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni) Healthcare Administration Database Medical Database ProQuest One Religion & Philosophy ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) SWEPUB Uppsala universitet full text SwePub SwePub Articles SWEPUB Freely available online SWEPUB Uppsala universitet SwePub Articles full text DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest One Religion & Philosophy Philosophy Collection ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Health Management Coronavirus Research Database ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest Health Management (Alumni Edition) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) Philosophy Database MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic Publicly Available Content Database MEDLINE |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Law |
| EISSN | 1472-6939 |
| EndPage | 14 |
| ExternalDocumentID | oai_doaj_org_article_3c00b3ccbe01479cb906d1229e6500a3 oai_DiVA_org_uu_527433 PMC11059645 A793094293 38689214 10_1186_s12910_024_01040_0 |
| Genre | Research Support, Non-U.S. Gov't Journal Article Comparative Study |
| GeographicLocations | France Sweden Egypt United States--US BRICS countries |
| GeographicLocations_xml | – name: France – name: Sweden – name: Egypt – name: United States--US – name: BRICS countries |
| GroupedDBID | --- 0R~ 23N 2WC 53G 5GY 5VS 6J9 6PF 7X7 88E 8FI 8FJ AABKS AAFWJ AAJSJ AASML AAWTL AAYXX ABIVO ABSDQ ABUWG ACGFO ACGFS ACHQT ACIHN ADBBV ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AHBYD AHMBA AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS AQUVI BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CITATION CS3 DIK DU5 E3Z EBD EBLON EBS EMB EMOBN F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IHR INH INR IOV IPY ISR ITC KPI KQ8 M0T M1P M48 M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO RBZ RNS ROL RPM RSV SHS SOJ SV3 TR2 UKHRP WOQ WOW XSB -A0 3V. ACRMQ ADINQ C24 CGR CUY CVF ECM EIF NPM PMFND 7XB 8FK AZQEC COVID DWQXO K9. PGAAH PJZUB PKEHL PPXIY PQEST PQUKI PRINS 7X8 5PM 2VQ 4.4 ACNBI ADTPV AHSBF AOWAS C1A D8T DF2 EJD H13 IPNFZ RIG ZZAVC PUEGO |
| ID | FETCH-LOGICAL-c654t-6d5d7e1ad0b4c3e2f86f059e6636c5bc886c27fc156fbffbc908f043d707dc973 |
| IEDL.DBID | M48 |
| ISSN | 1472-6939 |
| IngestDate | Wed Aug 27 01:30:34 EDT 2025 Thu Aug 21 07:33:20 EDT 2025 Thu Aug 21 18:34:33 EDT 2025 Fri Jul 11 03:46:22 EDT 2025 Sat Jul 26 03:36:42 EDT 2025 Tue Jun 17 22:11:27 EDT 2025 Tue Jun 10 21:08:33 EDT 2025 Fri Jun 27 05:46:34 EDT 2025 Fri Jun 27 05:54:10 EDT 2025 Fri Jun 27 06:04:51 EDT 2025 Wed Feb 19 02:04:01 EST 2025 Tue Jul 01 01:09:00 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Clinical trials Biomedical laws Social value Ethical principles Egypt |
| Language | English |
| License | 2024. The Author(s). Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c654t-6d5d7e1ad0b4c3e2f86f059e6636c5bc886c27fc156fbffbc908f043d707dc973 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| OpenAccessLink | https://www.proquest.com/docview/3054176698?pq-origsite=%requestingapplication% |
| PMID | 38689214 |
| PQID | 3054176698 |
| PQPubID | 42596 |
| PageCount | 14 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_3c00b3ccbe01479cb906d1229e6500a3 swepub_primary_oai_DiVA_org_uu_527433 pubmedcentral_primary_oai_pubmedcentral_nih_gov_11059645 proquest_miscellaneous_3049716686 proquest_journals_3054176698 gale_infotracmisc_A793094293 gale_infotracacademiconefile_A793094293 gale_incontextgauss_KPI_A793094293 gale_incontextgauss_ISR_A793094293 gale_incontextgauss_IOV_A793094293 pubmed_primary_38689214 crossref_primary_10_1186_s12910_024_01040_0 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2024-04-30 |
| PublicationDateYYYYMMDD | 2024-04-30 |
| PublicationDate_xml | – month: 04 year: 2024 text: 2024-04-30 day: 30 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | BMC medical ethics |
| PublicationTitleAlternate | BMC Med Ethics |
| PublicationYear | 2024 |
| Publisher | BioMed Central Ltd BioMed Central BMC |
| Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
| References | 1040_CR28 C Duggan (1040_CR56) 2014; 15 M Truong (1040_CR61) 2021; 18 CM Patino (1040_CR45) 2018; 44 B Gallagher (1040_CR32) 2016; 26 1040_CR20 1040_CR21 1040_CR22 1040_CR23 M Dooly (1040_CR1) 2017 JI Halonen (1040_CR3) 2020; 4 1040_CR25 1040_CR26 K Malterud (1040_CR44) 2020; 48 U Jonsson (1040_CR57) 2014; 38 1040_CR8 SN Whitney (1040_CR50) 2016; 12 WM Association (1040_CR55) 2013; 310 R Artal (1040_CR5) 2017; 43 D Marzouk (1040_CR19) 2021; 8 D Thaldar (1040_CR7) 2021; 4 SO Hansson (1040_CR58) 2006; 15 JH Sim (1040_CR15) 2019; 6 1040_CR34 1040_CR35 1040_CR36 1040_CR37 Y Chaaban (1040_CR27) 2021; 1 H Bomhof-Roordink (1040_CR43) 2019; 9 MG Habets (1040_CR62) 2014; 15 ACAL de Lemos Tavares (1040_CR16) 2022; 22 N Juth (1040_CR40) 2021; 35 T Haaser (1040_CR41) 2022; 17 EJ Emanuel (1040_CR10) 2008 C Pace (1040_CR54) 2003; 31 D Normile (1040_CR24) 2008; 322 1040_CR46 JM Tsoka-Gwegweni (1040_CR12) 2014; 9 1040_CR48 CH Braddock III (1040_CR60) 2021; 21 JJ Cameron (1040_CR59) 2019; 13 F Mutenherwa (1040_CR13) 2019; 19 NA Wages (1040_CR47) 2021; 108 MG Hansson (1040_CR30) 2006; 7 1040_CR17 1040_CR18 H Silverman (1040_CR52) 2013; 8 SY Guraya (1040_CR29) 2014; 2 N Juth (1040_CR39) 2017; 25 MV Johansen (1040_CR4) 2008; 55 D MacKay (1040_CR53) 2020; 20 SE Lindsay (1040_CR49) 2020; 28 H Paul (1040_CR6) 2018; 24 EJ Emanuel (1040_CR9) 2000; 283 K Norberg Wieslander (1040_CR31) 2023; 19 E Mantzaris (1040_CR14) 2017; 9 VA Miracle (1040_CR2) 2016; 35 1040_CR51 A Rid (1040_CR11) 2014; 384 D Harcourt (1040_CR33) 2014; 4 BC Groot (1040_CR42) 2019; 27 EJ Emanuel (1040_CR38) 2004; 189 |
| References_xml | – ident: 1040_CR26 – volume: 26 start-page: 586 issue: 7 year: 2016 ident: 1040_CR32 publication-title: Ethics Behavior doi: 10.1080/10508422.2015.1096207 – volume: 4 start-page: 409 year: 2021 ident: 1040_CR7 publication-title: BioLaw Journal-Rivista Di BioDiritto – volume: 7 start-page: 266 issue: 3 year: 2006 ident: 1040_CR30 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(06)70618-0 – ident: 1040_CR36 doi: 10.1177/1049732305276687 – volume: 189 start-page: 930 issue: 5 year: 2004 ident: 1040_CR38 publication-title: J Infect Dis doi: 10.1086/381709 – volume: 310 start-page: 2191 issue: 20 year: 2013 ident: 1040_CR55 publication-title: Jama doi: 10.1001/jama.2013.281053 – ident: 1040_CR23 doi: 10.1186/s43066-019-0010-y – volume: 17 start-page: 242 issue: 3 year: 2022 ident: 1040_CR41 publication-title: J Empirical Res Hum Res Ethics doi: 10.1177/15562646221093218 – ident: 1040_CR46 – volume: 322 start-page: 214 issue: 5899 year: 2008 ident: 1040_CR24 publication-title: Science. doi: 10.1126/science.322.5899.214 – volume: 1 start-page: 123 issue: 3 year: 2021 ident: 1040_CR27 publication-title: Akkad J Law Public Policy doi: 10.55202/ajlpp.v1i3.71 – volume: 6 start-page: 238212051988388 year: 2019 ident: 1040_CR15 publication-title: J Med Educ Curric Dev doi: 10.1177/2382120519883887 – volume: 55 start-page: 216 issue: 4 year: 2008 ident: 1040_CR4 publication-title: Dan Med Bull – volume: 35 start-page: 223 issue: 4 year: 2016 ident: 1040_CR2 publication-title: Dimens Crit Care Nurs doi: 10.1097/DCC.0000000000000186 – start-page: 123 volume-title: An ethical framework for biomedical research. The Oxford textbook of clinical research ethics year: 2008 ident: 1040_CR10 doi: 10.1093/oso/9780195168655.001.0001 – volume: 12 start-page: 182 issue: 4 year: 2016 ident: 1040_CR50 publication-title: Res Ethics doi: 10.1177/1747016116649993 – ident: 1040_CR35 – ident: 1040_CR48 doi: 10.1097/00005650-200003000-00010 – volume: 31 start-page: S121 issue: 3 year: 2003 ident: 1040_CR54 publication-title: Crit Care Med doi: 10.1097/01.CCM.0000054907.33928.48 – volume: 21 start-page: 28 issue: 2 year: 2021 ident: 1040_CR60 publication-title: Am J Bioeth doi: 10.1080/15265161.2020.1851812 – volume: 384 start-page: 1896 issue: 9957 year: 2014 ident: 1040_CR11 publication-title: Lancet doi: 10.1016/S0140-6736(14)61315-5 – ident: 1040_CR20 – volume: 4 start-page: 215824401454378 issue: 3 year: 2014 ident: 1040_CR33 publication-title: Sage Open doi: 10.1177/2158244014543782 – volume: 9 start-page: 36 issue: 5 year: 2014 ident: 1040_CR12 publication-title: J Empir Res Hum Res Ethics doi: 10.1177/1556264614553172 – ident: 1040_CR28 – volume: 9 start-page: e031763 issue: 12 year: 2019 ident: 1040_CR43 publication-title: BMJ Open doi: 10.1136/bmjopen-2019-031763 – volume: 28 start-page: 419 issue: 10 year: 2020 ident: 1040_CR49 publication-title: J Am Acad Orthopaedic Surgeons doi: 10.5435/JAAOS-D-19-00146 – volume: 8 start-page: 40 issue: 5 year: 2013 ident: 1040_CR52 publication-title: J Empir Res Hum Res Ethics doi: 10.1525/jer.2013.8.5.40 – volume: 13 start-page: e12506 issue: 11 year: 2019 ident: 1040_CR59 publication-title: Soc Personal Psychol Compass doi: 10.1111/spc3.12506 – ident: 1040_CR17 doi: 10.17576/malim-2020-2101-06 – ident: 1040_CR18 – volume: 27 start-page: 286 issue: 2 year: 2019 ident: 1040_CR42 publication-title: Educ Action Res doi: 10.1080/09650792.2018.1450771 – ident: 1040_CR34 – volume: 4 start-page: e503 issue: 11 year: 2020 ident: 1040_CR3 publication-title: Lancet Planetary Health doi: 10.1016/S2542-5196(20)30242-4 – volume-title: Research ethics. Research-publishing net year: 2017 ident: 1040_CR1 – volume: 283 start-page: 2701 issue: 20 year: 2000 ident: 1040_CR9 publication-title: Jama doi: 10.1001/jama.283.20.2701 – volume: 15 start-page: 285 issue: 3 year: 2006 ident: 1040_CR58 publication-title: Cambridge Quarterly of Healthcare Ethics doi: 10.1017/S0963180106060361 – volume: 19 start-page: 494 issue: 4 year: 2023 ident: 1040_CR31 publication-title: Res Ethics doi: 10.1177/17470161231179663 – volume: 18 start-page: 113 issue: 1 year: 2021 ident: 1040_CR61 publication-title: J Bioeth Inq doi: 10.1007/s11673-020-10069-w – ident: 1040_CR37 – volume: 108 start-page: 106517 year: 2021 ident: 1040_CR47 publication-title: Contemp Clin Trials doi: 10.1016/j.cct.2021.106517 – volume: 15 start-page: 1 issue: 1 year: 2014 ident: 1040_CR56 publication-title: Trials doi: 10.1186/1745-6215-15-335 – volume: 48 start-page: 617 issue: 6 year: 2020 ident: 1040_CR44 publication-title: Scandinavian J Public Health doi: 10.1177/1403494819863514 – volume: 15 start-page: 1 issue: 1 year: 2014 ident: 1040_CR62 publication-title: BMC Med Ethics doi: 10.1186/1472-6939-15-66 – volume: 2 start-page: 121 issue: 3 year: 2014 ident: 1040_CR29 publication-title: J Microscopy Ultrastructure doi: 10.1016/j.jmau.2014.03.003 – volume: 9 start-page: 91 issue: 8 year: 2017 ident: 1040_CR14 publication-title: Afr J Public Affairs – ident: 1040_CR21 – ident: 1040_CR25 – ident: 1040_CR8 doi: 10.1001/jama.2013.281053 – volume: 8 start-page: 715796 year: 2021 ident: 1040_CR19 publication-title: Front Med doi: 10.3389/fmed.2021.715796 – ident: 1040_CR51 doi: 10.1007/s10805-021-09430-4 – volume: 24 start-page: 1379 issue: 5 year: 2018 ident: 1040_CR6 publication-title: Sci Eng Ethics doi: 10.1007/s11948-017-9945-8 – volume: 44 start-page: 183 year: 2018 ident: 1040_CR45 publication-title: Jornal brasileiro de pneumologia doi: 10.1590/s1806-37562018000000164 – volume: 43 start-page: 107 year: 2017 ident: 1040_CR5 publication-title: Best Pract Re Clin Obstet Gynaecol doi: 10.1016/j.bpobgyn.2016.12.006 – volume: 22 start-page: 199 issue: 1 year: 2022 ident: 1040_CR16 publication-title: BMC Med Educ doi: 10.1186/s12909-022-03250-9 – volume: 20 start-page: 5 issue: 2 year: 2020 ident: 1040_CR53 publication-title: Am J Bioeth doi: 10.1080/15265161.2019.1701731 – volume: 19 start-page: 25 issue: 1 year: 2019 ident: 1040_CR13 publication-title: Dev World Bioeth doi: 10.1111/dewb.12191 – volume: 38 start-page: 1 issue: 1 year: 2014 ident: 1040_CR57 publication-title: Contemp Clin Trials doi: 10.1016/j.cct.2014.02.005 – ident: 1040_CR22 – volume: 25 start-page: 1 year: 2017 ident: 1040_CR39 publication-title: Health Care Analysis doi: 10.1007/s10728-014-0284-5 – volume: 35 start-page: 307 issue: 4 year: 2021 ident: 1040_CR40 publication-title: Bioethics doi: 10.1111/bioe.12786 |
| SSID | ssj0017832 |
| Score | 2.3215003 |
| Snippet | In this study, we examined the ethical implications of Egypt's new clinical trial law, employing the ethical framework proposed by Emanuel et al. and comparing... Background In this study, we examined the ethical implications of Egypt's new clinical trial law, employing the ethical framework proposed by Emanuel et al.... BackgroundIn this study, we examined the ethical implications of Egypt’s new clinical trial law, employing the ethical framework proposed by Emanuel et al. and... Background In this study, we examined the ethical implications of Egypt’s new clinical trial law, employing the ethical framework proposed by Emanuel et al.... Abstract Background In this study, we examined the ethical implications of Egypt’s new clinical trial law, employing the ethical framework proposed by Emanuel... |
| SourceID | doaj swepub pubmedcentral proquest gale pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database |
| StartPage | 48 |
| SubjectTerms | Bioethics Biomedical laws Biomedical research Biomedical Research - ethics Biomedical Research - legislation & jurisprudence Clinical trials Clinical Trials as Topic - ethics Clinical Trials as Topic - legislation & jurisprudence Committees Comparative analysis Egypt Ethical Analysis Ethical aspects Ethical principles Ethics Ethics Committees, Research Ethics, Research Etik European Union France Human Experimentation - ethics Human Experimentation - legislation & jurisprudence Human rights Human subjects Humans Informed Consent - ethics Informed Consent - legislation & jurisprudence International organizations Law Laws, regulations and rules Medical ethics Medical research Medicine, Experimental Pharmaceutical industry R&D Regulation Research & development Research & development expenditures Research ethics Research methodology Research Subjects - legislation & jurisprudence Social value Social Values Sweden |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQD4gL4k2goIBAHFBUx3Zs57jQVi2ogIBWvVl-tpVQFrEb8feZyWOpQagXrvFESr4Ze76Rx58JedEo0SZlQxWjbysRPKts4ryirk7esSBkjaeRjz7Ig2Px7rQ5vXTVF_aEjfLAI3A73FPquPcuAplXrXctlaFmrI3ALagddD4h583F1LR_oCBQ5yMyWu6sIKvhpi_DjgvsoaNZGhrU-v9eky8lpT8bJjNZ0SEV7d8iNycOWS7Gb79NrsXuDrl-NO2S3yW7i9L_FvUuI7a0g72d9EfKZSqB9pV7eAMZREc5n44sJ-Wf8_Kb_XmPHO_vfX17UE23JVReNmJdydAEFWsbqBOeR5a0TMCdIlAK6RvntZaeqeShYEsuJedbqhMVPCiqgm8Vv0-2umUXH5LSUpFUqOF3A1RvnLWNU07I4IOEEasL8noGz3wfRTHMUExoaUaoDUBtBqgNLcgbxHdjiYLWwwNws5ncbK5yc0Geo3cMSlZ02BNzZvvVyhx-PDELWGKgSAXe8i-jL5-vNnr_6TAzejUZpSV43NvpsALgg3pZmeV2Zgmz0-fDcziZaXVYGVhjBQpztoDks80wvokdb11c9mgjUN1LalmQB2P0bRDkWuqW1aIgOovLDOJ8pLs4H7TDa-TTUjQFeTmGcPbO7sXJYnBL35uGAbnkj_6H8x6TG2yYe7gJt0221j_6-AS43No9HabtL3sMRKU priority: 102 providerName: Directory of Open Access Journals – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV3db9QwDI_YkBAvCMbHCgMVBOIBVUuTNEmf0ME2bcAAAZvuLcpHs01C7VjvtH8fu5e7URDwWjtSajuOHTu_EPK8UqKOyoaiaXxdiOBZYSPnBXVl9I4FIUu8jXz4Ue4fiXfTapoO3PrUVrn0iYOjDp3HM_JtsEuBYIa1fn3-o8BXo7C6mp7QWCPXEboMW7rUdJVwlQrMdXlRRsvtHvY2LP0y7LvATjo62owGzP4_PfMvW9PvbZMjcNFhQ9q7TW6lSDKfLFR_h1xr2g2y9sFebpAbh6lifpfsTHJ_BfCdN9jeDqNswiLJu5hDCJjv4mtkYCn58qZknlCATvPv9vIeOdrb_fZ2v0gvJxReVmJWyFAF1ZQ2UCc8b1jUMkIc1UB4IX3lvNbSMxU9JG_Rxeh8TXWkggdFVfC14vfJetu1zSbJLRVRhRJ-OkAmx1ldOeWEDD5IoFidkVdLEZrzBUCGGRILLc1C4AYEbgaBG5qRNyjlFSeCWw8fuosTk9aK4Z5Sx713DeRvqvaupjKUjMH8K0otz8gz1JFB-IoW-2NO7LzvzcGnYzMBdwMJK8Qwf2P6-uX_TO8_H4yYXiam2IHevU0XF0A-iJ014twaccJK9WPy0qhM8hS9ubLrjDxdkXEkdr-1TTdHHoFIX1LLjDxY2OBKglxLXbNSZESPrHMk4jGlPTsdcMRLjK2lqDLyYmHIozE7Z8eTQS3zuakYBJr84b_n_4jcZMPawlLbFlmfXcybxxCxzdyTYVn-BEKqPe4 priority: 102 providerName: ProQuest |
| Title | A comparative ethical analysis of the Egyptian clinical research law |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/38689214 https://www.proquest.com/docview/3054176698 https://www.proquest.com/docview/3049716686 https://pubmed.ncbi.nlm.nih.gov/PMC11059645 https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-527433 https://doaj.org/article/3c00b3ccbe01479cb906d1229e6500a3 |
| Volume | 25 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV1Lb9QwELZKKyEuiDehZRUQiAMKdWzHjwNCW7pVC9pSFbbamxXbcVupytJ9CPj3jL3JlkCBazyJks8znpl4_A1CLwrBlBely6rKqow5S7LSU5phk3triGM8D6eRh4d8f8Q-jIvxGmrbHTUAzq5N7UI_qdH04s33yx_vwODfRoOXfHsGPits6ZJQTxEq5CCF3wDPJIKhDtnVroKQsWFZzgTJuKKqPURz7TM6jiry-f-5av_itn4vqewQj0ZntXcH3W6izLS_VIu7aK2q76Gbw2Yf_T7a7af2ivY7rULRO8iXDUNJOvEpBIbpIPQoA_1J2_OTacMNdJZelN8eoNHe4Mv7_azpp5BZXrB5xl3hRJWXDhtmaUW85B6iqwqCDm4LY6XklghvIaXzxntjFZYeM-oEFs4qQR-i9XpSV49RWmLmhcvhcx3kd5SowgjDuLOOw0gpE_S6BU9_XdJm6JhuSK6XUGuAWkeoNU7QTsB3JRkor-OFyfRUNxakqcXYUGtNBVmdUNYozF1OCLx_gXFJE_Q8zI4OpBZ1qJo5LRezmT74dKL7sAhBGguRzd-EPh__X-jj0UFH6FUj5Ccw47ZsjjMAPoFRqyO51ZEE-7Xd4VaddKv-GlZhFqg7FSD5bDUc7gw1cXU1WQQZFvi_uOQJerTUvhWCVHKpSM4SJDt62YG4O1Kfn0V28TxE3JwVCXq5VOHOPbvnJ_04LYuFLgiEn_TJvz9vE90i0arCBtwWWp9PF9VTiOPmpoduiLHooY2dweHRcS_-DelFg_0JfCVE0g |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEF61qQRcEBQohgIGUXFAVte767V9QCglqRLyoCpt1dvifbWVkF2aRBF_it_IrB8pBgGnXr2zkT07z8zsNwi9jmKW2jjTgTEqDZhWJMgspQGWoVWSaMZDdxt5MuWDY_bxNDpdQz-auzCurbKxiaWh1oVy_5HvglwyB2aYJu8vvwVuapSrrjYjNCqxGJnvS0jZZu-GPTjfHUL2-0cfBkE9VSBQPGLzgOtIxybMNJZMUUNswi3EGAZcL1eRVEnCFYmtgsTGSmulSnFiMaM6xrFWaUzhd9fRBqOQynTQxl5_enC4qlvEoCDN1ZyE787Am7piM3GdHq53D7fcXzkl4E9f8Isz_L1RswVnWrrA_Xvobh27-t1K2O6jNZNvovVxttxEtyZ1jf4B6nV9dQ0p7hvXUA-7shr9xC-sD0Gn33fzz0A2_eZupl_jDp37X7PlQ3R8I1x9hDp5kZvHyM8ws7EO4aM15I6UpJGMJeNaaQ4rWeKhtw0LxWUFySHKVCbhomK4AIaLkuECe2jPcXlF6eC0ywfF1ZmotVNQhbGkSkkDGWOcKplirkNC4P0jjDPqoVfujIQDzMhdR85ZtpjNxPDTieiCgYMUGaKmvxF9Pvw_0ehg2CJ6UxPZAs5dZfVVCeCPQ-tqUW63KME2qPZyI1Sitk0zca1JHnq5WnY7Xb9dboqFo2EOW4wn3ENblQyuOEgTnqQkZB5KWtLZYnF7Jb84L5HLQxfNcxZ5aKcS5Nae3sVJtzyWxUJEBEJb-uTf7_8C3R4cTcZiPJyOnqI7pNQzV-jbRp351cI8g3hxLp_XSuqjLzdtF34CCBl9Sw |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+comparative+ethical+analysis+of+the+Egyptian+clinical+research+law&rft.jtitle=BMC+medical+ethics&rft.au=Martin%2C+Sylvia&rft.au=Ancillotti%2C+Mirko&rft.au=Slokenberga%2C+Santa&rft.au=Matar%2C+Amal&rft.date=2024-04-30&rft.pub=BioMed+Central+Ltd&rft.issn=1472-6939&rft.eissn=1472-6939&rft.volume=25&rft.issue=1&rft_id=info:doi/10.1186%2Fs12910-024-01040-0&rft.externalDocID=A793094293 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1472-6939&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1472-6939&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1472-6939&client=summon |